Health systems are looking for new options for pain management in the wake of the opioid epidemic.
The nation’s opioid epidemic has health systems looking for safer ways to provide pain relief while still helping patients achieve other goals, such as avoiding a hospital readmission.
A recent study from researchers at Duke University and the University of Washington School of Pharmacy has found that using intravenous (IV) acetaminophen to manage pain helped reduce opioid use, limit the chances of hospital readmission, and hold down costs.
The study was presented last week at the 28th annual National Forum of the Institute for Healthcare Improvement, held in Orlando, Florida, according to a statement from Mallinckrodt Pharmaceuticals, the maker of Ofirmev (injectable acetaminophen). The study compared outcomes among 190,691 patients who had total knee replacement from 2012 to 2015, including 56,475 (30%) who received IV acetaminophen.
Patients who received the IV acetaminophen as part of their pain management regimen had shorter length of stay in the hospital (2.8 days compared with 3.0 days). They were less likely to be readmitted in 30 days, less likely to be discharged to a skilled nursing facility, and more likely to be discharged home. They also had lower overall healthcare costs: $16,214.60 (SD = $6950.20) for the IV acetaminophen compared with $16,750.40 (SD = $9634.60) for those oral treatment only.
The finding that IV acetaminophen could be an effective treatment for pain management is important, given how many people become dependent on opioids after being prescribed the pills by a doctor. A study in The Journal of Pain found that 27% of those reporting chronic opioid use said they started using the pills after surgery and another 27% started using them after an acute injury. Deaths from opioid abuse have increased 200% since 2000, and last week the CDC reported the opioid crisis is a reason that US life expectancy dropped for the first time since 1993.
Reference
Pham AT, Hansen R, Boing EA, Triple aim as a conceptual framework for conducting comparative effectiveness research in postoperative pain. Presented at the 28th Annual National Forum for the Institute for Healthcare Improvement, Orlando, Florida. December 4-7, 2016. Poster 194.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Survey Results Reveal Potential Factors Slowing the Decline in Cardiovascular Mortality Rate
April 23rd 2024Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.
Read More
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More